Search

Your search keyword '"Galeota-Lanza, Alfonso"' showing total 25 results
Start Over Author "Galeota-Lanza, Alfonso"
25 results on '"Galeota-Lanza, Alfonso"'

1. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients

Author

Pontillo, Giuseppina, Pignata, Luca, Attanasio, Maria Rosaria, Lieto, Raffaele, Cutolo, Francesco, Cuomo, Marianna, Guarino, Maria, Esposito, Ilaria, Portella, Giuseppe, Cossiga, Valentina, Loperto, Ilaria, Tortora, Raffaella, Cennamo, Michele, Capasso, Mario, Terracciano, Daniela, Galeota Lanza, Alfonso, Di Somma, Sarah, Picciotto, Francesco Paolo, and Morisco, Filomena

Published
2022
Full Text
View/download PDF

2. Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study

Author

Sciarrone, Salvatore Stefano, Ferrarese, Alberto, Bizzaro, Debora, Volpato, Sofia, Donato, Francesca Maria, Invernizzi, Federica, Trespidi, Laura, Ramezzana, Ilaria Giuditta, Avolio, Alfonso Wolfango, Nure, Erida, Pascale, Marco Maria, Fagiuoli, Stefano, Pasulo, Luisa, Merli, Manuela, Lapenna, Lucia, Toniutto, Pierluigi, Lenci, Ilaria, Di Donato, Roberto, De Maria, Nicola, Villa, Erica, Galeota Lanza, Alfonso, Marenco, Simona, Bhoori, Sherrie, Mameli, Laura, Cillo, Umberto, Boccagni, Patrizia, Russo, Francesco Paolo, Bo, Patrizio, Cosmi, Erich, and Burra, Patrizia

Published
2022
Full Text
View/download PDF

4. Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti–Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation

Author

Macera, Margherita, Stanzione, Maria, Messina, Vincenzo, D'Adamo, Giuseppe, Sangiovanni, Vincenzo, Mioglioresi, Lucia, Fontanella, Luca, De Pascalis, Stefania, Stornaiuolo, Gianfranca, Galeota Lanza, Alfonso, Ascione, Tiziana, Sagnelli, Evangelista, Gentile, Ivan, Piai, Guido, Gaeta, Giovanni Battista, and Coppola, Nicola

Published
2017
Full Text
View/download PDF

6. Bridging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta‐analysis on intention‐to‐treat outcomes

Author

Di Martino, Marcello, primary, Ferraro, Daniele, additional, Pisaniello, Donatella, additional, Arenga, Giuseppe, additional, Falaschi, Federica, additional, Terrone, Alfonso, additional, Maniscalco, Marilisa, additional, Galeota Lanza, Alfonso, additional, Esposito, Ciro, additional, and Vennarecci, Giovanni, additional

Published
2022
Full Text
View/download PDF

7. Downstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes

Author

Di Martino, Marcello, primary, Vitale, Alessandro, additional, Ferraro, Daniele, additional, Maniscalco, Marilisa, additional, Pisaniello, Donatella, additional, Arenga, Giuseppe, additional, Falaschi, Federica, additional, Terrone, Alfonso, additional, Iacomino, Alessandro, additional, Galeota Lanza, Alfonso, additional, Esposito, Ciro, additional, Cillo, Umberto, additional, and Vennarecci, Giovanni, additional

Published
2022
Full Text
View/download PDF

8. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients

Author

Guarino, Maria, primary, Esposito, Ilaria, additional, Portella, Giuseppe, additional, Cossiga, Valentina, additional, Loperto, Ilaria, additional, Tortora, Raffaella, additional, Cennamo, Michele, additional, Capasso, Mario, additional, Terracciano, Daniela, additional, Galeota Lanza, Alfonso, additional, Di Somma, Sarah, additional, Picciotto, Francesco Paolo, additional, Morisco, Filomena, additional, Pontillo, Giuseppina, additional, Pignata, Luca, additional, Attanasio, Maria Rosaria, additional, Lieto, Raffaele, additional, Cutolo, Francesco, additional, and Cuomo, Marianna, additional

Published
2022
Full Text
View/download PDF

9. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes

Author

Carrai, Paola, Morelli, Cristina, Cordone, Gabriella, Romano, Antonietta, Tamé, Mariarosa, Lionetti, Raffaella, Pietrosi, Giada, Lenci, Ilaria, Piai, Guido, Russo, Francesco Paolo, Coppola, Carmine, Melazzini, Mario, Montilla, Simona, Pani, Luca, Petraglia, Sandra, Russo, Pierluigi, Trotta, Maria Paola, Martini, Silvia, Toniutto, Pierluigi, Bandiera, Francesco, Bhoori, Sherrie, Brillanti, Stefano, Burra, Patrizia, Corsale, Sveva, De Luca, Andrea, Fagiuoli, Stefano, Fattovich, Giovanna, Fava, Gianmarco, Felder, Martina, Forte, Paolo, Galeota‐Lanza, Alfonso, Gitto, Stefano, Grieco, Antonio, Grossi, Paolo, Ialungo, A.M., Iemmolo, Rosa Maria, Loiacono, Laura, Mangia, Alessandra, Merli, Manuela, Piacentini, A., Pellicelli, Adriano, Rigamonti, Cristina, Gabriella, Verucchi, and Zignego, Anna Linda

Published
2017
Full Text
View/download PDF

10. Bridging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta‐analysis on intention‐to‐treat outcomes.

Author

Di Martino, Marcello, Ferraro, Daniele, Pisaniello, Donatella, Arenga, Giuseppe, Falaschi, Federica, Terrone, Alfonso, Maniscalco, Marilisa, Galeota Lanza, Alfonso, Esposito, Ciro, and Vennarecci, Giovanni

Abstract

Introduction: Locoregional therapies are commonly used as bridging strategies to decrease the drop‐out of patients with hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). The present paper aims to assess the outcomes of bridging therapies in patients with HCC considered for LT according to an intention‐to‐treat (ITT) survival analysis. Material and methods: Medline and Web of Science databases were searched for reports published before May 2021. Papers assessing adult patients with HCC considered for LT and reporting ITT survival outcomes were included. Two reviewers independently identified, extracted the data, and evaluated the papers according to Newcastle‐Ottawa criteria. Outcomes analyzed were: drop‐out rate; time on the waiting list; 1‐, 3‐, and 5‐year survival after LT and based on an ITT analysis. Results: The search identified 3106 records; six papers (1043 patients) met the inclusion criteria. Patients with HCC, listed for LT and submitted to bridging therapies presented a longer waiting time before LT (MD 3.77, 95% CI 2.07‐5.48) in comparison with the non‐interventional group. However, they presented a raised post LT after 1‐year (OR 2.00, 95% CI 1.18‐3.41), 3‐years (OR 1.47, 95% CI 1.01‐2.15), and 5‐years (OR 1.50, 95% CI 1.06‐2.13) survival. Conclusion: Patients submitted to bridging procedures, despite having a longer interval on the waiting list, presented better post‐LT survival outcomes. Bridging therapies for selected patients at low risk of post‐procedural complications and long expected intervals on the waiting list should be encouraged. However, further clinical trials should confirm the survival benefit of bridging therapies in patients with HCC listed for LT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study

Author

Sciarrone, Salvatore Stefano, primary, Ferrarese, Alberto, additional, Bizzaro, Debora, additional, Volpato, Sofia, additional, Donato, Francesca Maria, additional, Invernizzi, Federica, additional, Trespidi, Laura, additional, Ramezzana, Ilaria Giuditta, additional, Avolio, Alfonso Wolfango, additional, Nure, Erida, additional, Pascale, Marco Maria, additional, Fagiuoli, Stefano, additional, Pasulo, Luisa, additional, Merli, Manuela, additional, Lapenna, Lucia, additional, Toniutto, Pierluigi, additional, Lenci, Ilaria, additional, Di Donato, Roberto, additional, De Maria, Nicola, additional, Villa, Erica, additional, Galeota Lanza, Alfonso, additional, Marenco, Simona, additional, Bhoori, Sherrie, additional, Mameli, Laura, additional, Cillo, Umberto, additional, Boccagni, Patrizia, additional, Russo, Francesco Paolo, additional, Bo, Patrizio, additional, Cosmi, Erich, additional, and Burra, Patrizia, additional

Published
2021
Full Text
View/download PDF

14. Outcomes of Liver Transplant for Adults With Wilson’s Disease

Author

Ferrarese, Alberto, primary, Morelli, Maria Cristina, additional, Carrai, Paola, additional, Milana, Martina, additional, Angelico, Mario, additional, Perricone, Giovanni, additional, Belli, Luca Saverio, additional, Marrone, Giuseppe, additional, Grieco, Antonio, additional, Martini, Silvia, additional, Manini, Matteo Angelo, additional, Fagiuoli, Stefano, additional, Toniutto, Pierluigi, additional, Galeota Lanza, Alfonso, additional, Bhoori, Sherrie, additional, Petta, Salvatore, additional, Giannini, Edoardo G., additional, and Burra, Patrizia, additional

Published
2020
Full Text
View/download PDF

16. Hepatitis C late relapse in patients with directly acting antiviral‐related sustained virological response at week 12

Author

Pisaturo, Mariantonietta, primary, Minichini, Carmine, additional, Starace, Mario, additional, Caroprese, Mara, additional, Macera, Margherita, additional, Brancaccio, Giuseppina, additional, De Pascalis, Stefania, additional, Santonicola, Antonella, additional, Galeota Lanza, Alfonso, additional, Zampino, Rosa, additional, Cotticelli, Gaetano, additional, Sagnelli, Evangelista, additional, Gaeta, Giovanni Battista, additional, and Coppola, Nicola, additional

Published
2019
Full Text
View/download PDF

17. HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets

Author

Colagrossi, Luna, primary, Salpini, Romina, additional, Scutari, Rossana, additional, Carioti, Luca, additional, Battisti, Arianna, additional, Piermatteo, Lorenzo, additional, Bertoli, Ada, additional, Fabeni, Lavinia, additional, Minichini, Carmine, additional, Trimoulet, Pascale, additional, Fleury, Hervé, additional, Nebuloso, Elena, additional, De Cristofaro, Maria, additional, Cappiello, Giuseppina, additional, Spanò, Alberto, additional, Malagnino, Vincenzo, additional, Mari, Terenzio, additional, Barlattani, Angelo, additional, Iapadre, Nerio, additional, Lichtner, Miriam, additional, Mastroianni, Claudio, additional, Lenci, Ilaria, additional, Pasquazzi, Caterina, additional, De Sanctis, Giuseppe, additional, Galeota Lanza, Alfonso, additional, Stanzione, Maria, additional, Stornaiuolo, Gianfranca, additional, Marignani, Massimo, additional, Sarmati, Loredana, additional, Andreoni, Massimo, additional, Angelico, Mario, additional, Ceccherini-Silberstein, Francesca, additional, Perno, Carlo-Federico, additional, Coppola, Nicola, additional, and Svicher, Valentina, additional

Published
2018
Full Text
View/download PDF

18. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: A randomized trial

Author

Di Costanzo, Giovan Giuseppe, primary, Tortora, Raffaella, additional, D'Adamo, Giuseppe, additional, De Luca, Massimo, additional, Lampasi, Filippo, additional, Addario, Luigi, additional, Galeota Lanza, Alfonso, additional, Picciotto, Francesco Paolo, additional, Tartaglione, Maria Teresa, additional, Cordone, Gabriella, additional, Imparato, Michele, additional, Mattera, Silvana, additional, and Pacella, Claudio Maurizio, additional

Published
2015
Full Text
View/download PDF

19. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.

Author

Origa, Raffaella, Ponti, Maria Laura, Filosa, Aldo, Galeota Lanza, Alfonso, Piga, Antonio, Saracco, Giorgio Maria, Pinto, Valeria, Picciotto, Antonino, Rigano, Paolo, Madonia, Salvatore, Rosso, Rosamaria, D'Ascola, Domenico, Cappellini, Maria Domenica, D'Ambrosio, Roberta, Tartaglione, Immacolata, De Franceschi, Lucia, Gianesin, Barbara, Di Marco, Vito, and Forni, Gian Luca

Published
2017
Full Text
View/download PDF

20. Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study

Author

Addario, Luigi, primary, Scaglione, Giuseppe, additional, Tritto, Giovanni, additional, Di Costanzo, Giovan Giuseppe, additional, De Luca, Massimo, additional, Lampasi, Filippo, additional, Galeota Lanza, Alfonso, additional, Picciotto, Francesco P., additional, Teresa Tartaglione, Maria, additional, Utech, Wanda, additional, Macr`, Michela, additional, Giannelli, Eduardo, additional, and Ascione, Antonio, additional

Published
2006
Full Text
View/download PDF

21. High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy.

Author

De Marco, Francesco, Liguori, Rosario, Giardina, Maria Grazia, D'Armiento, Maria, Angelucci, Emanuele, Lucariello, Antonio, Morante, Roberto, Cimino, Lucia, Galeota-Lanza, Alfonso, Tarantino, Giovanni, Ascione, Antonio, Budillon, Gabriele, Vecchione, Raffaela, Martinelli, Rosanna, Matarazzo, Margherita, and De Simone, Vincenzo

Subjects
HEMOCHROMATOSIS, GENES, IRON metabolism, LIVER diseases, MELANODERMA
Abstract

Hereditary haemochromatosis is an autosomal recessive disorder of iron regulation that results in abnormal intestinal iron absorption with progressive iron overloading of parenchymal cells.Two specific,single point mutations of the HFE gene (C282Y and H63D) have been described in haemochromatosis patients. Epidemiological studies have revealed a strict association between hereditary haemochromatosis and C282Y homozygosis or C282Y/H63D compound heterozygosis,suggesting that these mutations may provide a useful tool for diagnosis.However,recent investigations from southern Europe have reported lower allelic frequencies of the C282Y mutation among haemochromatosis patients,apparently depending on the geographical area of the population analysed.To assess the predictive value of the detection of the C282Y and H63D HFE mutations in our geographical area,we have evaluated their occurrence in 46 haemochromatosis patients from southern Italy. We found that only 19.6%of our patients were homozygous for the C282Y mutation and 21.7%were compound C282Y/H63D heterozygotes.Among the remaining 59%,approximately 40%did not display any of the known HFE mutations.We conclude that, in southern Italy,another genetic determinant/s must be responsible for many haemochromatosis cases and that a genetic screening for the C282Y and H63D HFE mutations is not sufficient for hereditary haemochromatosis diagnosis. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

22. COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study

Author

Maria Guarino, Valentina Cossiga, Ilaria Loperto, Ilaria Esposito, Rosanna Ortolani, Andrea Fiorentino, Giuseppina Pontillo, Lucia De Coppi, Valentina Cozza, Alfonso Galeota Lanza, Giovanni Giuseppe Di Costanzo, Francesco Paolo Picciotto, Filomena Morisco, Guarino, Maria, Cossiga, Valentina, Loperto, Ilaria, Esposito, Ilaria, Ortolani, Rosanna, Fiorentino, Andrea, Pontillo, Giuseppina, De Coppi, Lucia, Cozza, Valentina, Galeota Lanza, Alfonso, Di Costanzo, Giovanni Giuseppe, Picciotto, Francesco Paolo, and Morisco, Filomena

Subjects
Adult, Hospitalization, Male, Multidisciplinary, SARS-CoV-2, Incidence, COVID-19, Humans, Female, Prospective Studies, Middle Aged, Liver Transplantation
Abstract

Liver transplant (LT) recipients are vulnerable to SARS-CoV-2-infection (COVID-19), due to immunosuppression and comorbidities. This study aimed to evaluate the impact of COVID-19 on LT recipients compared to general population in the Campania region. In this prospective double-centre study, we enrolled all consecutive adult LT recipients with confirmed SARS-CoV-2-infection. Data were collected at diagnosis of COVID-19 and during follow-up and compared with the regional population. Thirty LT recipients (3.28%) developed SARS-CoV-2-infection (76.66% male, median age 62.61 years). Sixteen (53.33%) were symptomatic. Common symptoms were fever, cough, fatigue, and anosmia. Twenty-five (83.33%) were outpatients, 5 (16.66%) required hospitalization (6.66% admitted to Intensive Care Unit, 6.62% developed Acute Respiratory Distress Syndrome and 6.66% died). Immunosuppressors were in 3 (10%) patients. Incidence rate of COVID-19 was similar between LT patients and general population (3.28% vs 4.37%, p = 0.142) with higher rate of symptoms in LT patients (53.33% vs 15.87%, p

Published
2021

23. First report of successful liver transplant with graft from a JAK-2 positive essential thrombocythemia donor and common hepatic artery thrombosis

Author

Giovanni Vennarecci, Alfonso Galeota Lanza, Claudio Napoli, Marcello Di Martino, Daniele Ferraro, Ferraro, Daniele, Di Martino, Marcello, Napoli, Claudio, Galeota Lanza, Alfonso, and Vennarecci, Giovanni

Subjects
Hepatic Artery, Liver Diseases, Living Donors, Gastroenterology, Humans, Thrombosis, Tissue Donors, Liver Transplantation, Retrospective Studies, Thrombocythemia, Essential
Published
2022
Full Text
View/download PDF

24. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes

Author

Carrai, P, Morelli, C, Cordone, G, Romano, A, Tamé, M, Lionetti, R, Pietrosi, G, Lenci, I, Piai, G, Russo, F, Coppola, C, Melazzini, M, Montilla, S, Pani, L, Petraglia, S, Russo, P, Trotta, M, Martini, S, Toniutto, P, the ITACOPS study group, Bandiera, F, Bhoori, S, Brillanti, S, Burra, P, Corsale, S, De Luca, A, Fagiuoli, S, Fattovich, G, Fava, G, Felder, M, Forte, P, Galeota-Lanza, A, Gitto, S, Grieco, A, Grossi, P, Ialungo, A, Iemmolo, R, Loiacono, L, Mangia, A, Merli, M, Piacentini, A, Pellicelli, A, Rigamonti, C, Gabriella, V, Zignego, A. L., Carrai, P, Morelli, C, Cordone, G, Romano, A, Tame, M, Lionetti, R, Pietrosi, G, Lenci, I, Piai, G, Russo, F, Coppola, C, Melazzini, M, Montilla, S, Pani, L, Petraglia, S, Russo, P, Trotta, M, Martini, S, Toniutto, P, Bandiera, F, Bhoori, S, Brillanti, S, Burra, P, Corsale, S, De Luca, A, Fagiuoli, S, Fattovich, G, Fava, G, Felder, M, Forte, P, Galeota-Lanza, A, Gitto, S, Grieco, A, Grossi, P, Ialungo, A, Iemmolo, R, Loiacono, L, Mangia, A, Merli, M, Piacentini, A, Pellicelli, A, Rigamonti, C, Gabriella, V, Zignego, A, Carrai, Paola, Cristina, Morelli, Cordone, Gabriella, Romano, Antonietta, Tamã©, Mariarosa, Lionetti, Raffaella, Pietrosi, Giada, Lenci, Ilaria, Piai, Guido, Russo, Francesco Paolo, Coppola, Carmine, Melazzini, Mario, Montilla, Simona, Pani, Luca, Petraglia, Sandra, Russo, Pierluigi, Trotta, Maria Paola, Martini, Silvia, Toniutto, Pierluigi, Bandiera, Francesco, Bhoori, Sherrie, Brillanti, Stefano, Burra, Patrizia, Corsale, Sveva, De Luca, Andrea, Fagiuoli, Stefano, Fattovich, Giovanna, Fava, Gianmarco, Felder, Martina, Forte, Paolo, Galeota-Lanza, Alfonso, Gitto, Stefano, Grieco, Antonio, Grossi, Paolo, Ialungo, A. M., Iemmolo, Rosa Maria, Loiacono, Laura, Mangia, Alessandra, Merli, Manuela, Piacentini, A., Pellicelli, Adriano, Rigamonti, Cristina, Gabriella, Verucchi, and Zignego, Anna Linda

Subjects
Compassionate Use Trials, Liver Cirrhosis, Male, 0301 basic medicine, Simeprevir, cholestatic hepatiti, cholestatic hepatitis, hepatitis C, liver transplantation, sofosbuvir, Analysis of Variance, Antiviral Agents, Cohort Studies, Confidence Intervals, Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Hepatitis C, Chronic, Humans, Italy, Liver Function Tests, Logistic Models, Multivariate Analysis, Prognosis, Recurrence, Ribavirin, Risk Assessment, Severity of Illness Index, Sofosbuvir, Treatment Outcome, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Chronic, Hepatitis C, Combination, 030211 gastroenterology & hepatology, Drug, Viral hepatitis, medicine.drug, medicine.medical_specialty, Daclatasvir, Transplantation, Dose-Response Relationship, 03 medical and health sciences, Drug Therapy, Internal medicine, medicine, business.industry, medicine.disease, digestive system diseases, Surgery, 030104 developmental biology, chemistry, Liver function, business
Abstract

Direct antivirals are available for treating recurrent hepatitis C (RHC). This study reported outcomes of 424 patients with METAVIR F3–F4 RHC who were treated for 24 weeks with sofosbuvir/ribavirin and followed for 12 weeks within the Italian sofosbuvir compassionate use program. In 55 patients, daclatasvir or simeprevir were added. Child–Pugh class and model of end stage liver disease (MELD) scores were evaluated at baseline and 36 weeks after the start of therapy. The sustained viral response (SVR) was 86.7% (316/365) in patients who received sofosbuvir/ribavirin and 98.3% (58/59) in patients who received a second antiviral (P < 0.01). In patients treated with sofosbuvir/ribavirin, a significant difference in SVR was observed between patients diagnosed with METAVIR F4 (211/250; 84.4%), METAVIR F3 (95/105; 90.5%) and fibrosing cholestatic hepatitis (10/10; 100%) (P = 0.049). A significant association was found between patients who worsened from Child–Pugh class A and who experienced viral relapse (4/26 vs. 8/189, P = 0.02). In patients with a baseline MELD score

Published
2017

25. Bridging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis on intention-to-treat outcomes.

Author

Di Martino M, Ferraro D, Pisaniello D, Arenga G, Falaschi F, Terrone A, Maniscalco M, Galeota Lanza A, Esposito C, and Vennarecci G

Subjects
Adult, Humans, Intention to Treat Analysis, Treatment Outcome, Carcinoma, Hepatocellular surgery, Liver Neoplasms surgery, Liver Transplantation methods
Abstract

Introduction: Locoregional therapies are commonly used as bridging strategies to decrease the drop-out of patients with hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). The present paper aims to assess the outcomes of bridging therapies in patients with HCC considered for LT according to an intention-to-treat (ITT) survival analysis., Material and Methods: Medline and Web of Science databases were searched for reports published before May 2021. Papers assessing adult patients with HCC considered for LT and reporting ITT survival outcomes were included. Two reviewers independently identified, extracted the data, and evaluated the papers according to Newcastle-Ottawa criteria. Outcomes analyzed were: drop-out rate; time on the waiting list; 1-, 3-, and 5-year survival after LT and based on an ITT analysis., Results: The search identified 3106 records; six papers (1043 patients) met the inclusion criteria. Patients with HCC, listed for LT and submitted to bridging therapies presented a longer waiting time before LT (MD 3.77, 95% CI 2.07-5.48) in comparison with the non-interventional group. However, they presented a raised post LT after 1-year (OR 2.00, 95% CI 1.18-3.41), 3-years (OR 1.47, 95% CI 1.01-2.15), and 5-years (OR 1.50, 95% CI 1.06-2.13) survival., Conclusion: Patients submitted to bridging procedures, despite having a longer interval on the waiting list, presented better post-LT survival outcomes. Bridging therapies for selected patients at low risk of post-procedural complications and long expected intervals on the waiting list should be encouraged. However, further clinical trials should confirm the survival benefit of bridging therapies in patients with HCC listed for LT., (© 2022 Japanese Society of Hepato-Biliary-Pancreatic Surgery.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results